FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307426601> ?p ?o ?g. }

• W4307426601 endingPage "42" @default.
• W4307426601 startingPage "33" @default.
• W4307426601 abstract "Fenfluramine, tradename Fintepla®, was appraised within the National Institute for Health and Care Excellence (NICE) single technology appraisal (STA) process as Technology Appraisal 808. Within the STA process, the company (Zogenix International) provided NICE with a written submission and a mathematical health economic model, summarising the company’s estimates of the clinical effectiveness and cost-effectiveness of fenfluramine for patients with Dravet syndrome (DS). This company submission (CS) was reviewed by an evidence review group (ERG) independent of NICE. The ERG, Kleijnen Systematic Reviews in collaboration with Maastricht University Medical Centre, produced an ERG report. This paper presents a summary of the ERG report and the development of the NICE guidance. The CS included a systematic review of the evidence for fenfluramine. From this review the company identified and presented evidence from two randomised trials (Study 1 and Study 1504), an open-label extension study (Study 1503) and ‘real world evidence’ from a prospective and retrospective study. Both randomised trials were conducted in patients up to 18 years of age with DS, whose seizures were incompletely controlled with previous anti-epileptic drugs. A Bayesian network meta-analysis was performed to compare fenfluramine with cannabidiol plus clobazam. There was no evidence of a difference between any doses of fenfluramine and cannabidiol in the mean convulsive seizure frequency (CSF) rate during treatment. However, fenfluramine increased the number of patients achieving ≥ 50% reduction in CSF frequency from baseline compared to cannabidiol. The company used an individual-patient state-transition model (R version 3.5.2) to model cost-effectiveness of fenfluramine. The CSF and convulsive seizure-free days were estimated using patient-level data from the placebo arm of the fenfluramine registration studies. Subsequently, a treatment effect of either fenfluramine or cannabidiol was applied. Utility values for the economic model were obtained by mapping Pediatric Quality of Life Inventory data from the registration studies to EuroQol-5D-3L Youth (EQ-5D-Y-3L). The company included caregiver utilities in their base-case, as the severe needs of patients with DS have a major impact on parents and caregivers. There were several key issues. First, the company included caregiver utilities in the model in a way that when patients in the economic model died, the corresponding caregiver utility was also set to zero. Second, the model was built in R statistical software, resulting in transparency issues. Third, the company assumed the same percentage reduction for convulsive seizure days as was estimated for CSF. Fourth, during the final appraisal committee meeting, influential changes were made to the model that were not in line with the ERG’s preferences (but were accepted by the appraisal committee). The company’s revised and final incremental cost effectiveness ratio (ICER) in line with committee preferences resulted in fenfluramine dominating cannabidiol. Fenfluramine was recommended as an add-on to other antiepileptic medicines for treating seizures associated with DS in people aged 2 years and older in the National Health Service (NHS)." @default.
• W4307426601 created "2022-11-01" @default.
• W4307426601 creator A5003126498 @default.
• W4307426601 creator A5016388439 @default.
• W4307426601 creator A5016739173 @default.
• W4307426601 creator A5021404933 @default.
• W4307426601 creator A5040279436 @default.
• W4307426601 creator A5041959705 @default.
• W4307426601 creator A5046578778 @default.
• W4307426601 creator A5059685514 @default.
• W4307426601 creator A5065740152 @default.
• W4307426601 creator A5069841995 @default.
• W4307426601 creator A5075448540 @default.
• W4307426601 creator A5080751461 @default.
• W4307426601 creator A5084498269 @default.
• W4307426601 date "2022-10-27" @default.
• W4307426601 modified "2023-10-14" @default.
• W4307426601 title "Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal" @default.
• W4307426601 cites W1926532831 @default.
• W4307426601 cites W1977614971 @default.
• W4307426601 cites W2013564592 @default.
• W4307426601 cites W2399319535 @default.
• W4307426601 cites W2540532044 @default.
• W4307426601 cites W2620218661 @default.
• W4307426601 cites W2979896320 @default.
• W4307426601 cites W2989575580 @default.
• W4307426601 cites W2996672198 @default.
• W4307426601 cites W3009130471 @default.
• W4307426601 cites W3042990227 @default.
• W4307426601 cites W3194137475 @default.
• W4307426601 cites W4307426601 @default.
• W4307426601 cites W4317390067 @default.
• W4307426601 doi "https://doi.org/10.1007/s40273-022-01209-8" @default.
• W4307426601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36301414" @default.
• W4307426601 hasPublicationYear "2022" @default.
• W4307426601 type Work @default.
• W4307426601 citedByCount "4" @default.
• W4307426601 countsByYear W43074266012022 @default.
• W4307426601 countsByYear W43074266012023 @default.
• W4307426601 crossrefType "journal-article" @default.
• W4307426601 hasAuthorship W4307426601A5003126498 @default.
• W4307426601 hasAuthorship W4307426601A5016388439 @default.
• W4307426601 hasAuthorship W4307426601A5016739173 @default.
• W4307426601 hasAuthorship W4307426601A5021404933 @default.
• W4307426601 hasAuthorship W4307426601A5040279436 @default.
• W4307426601 hasAuthorship W4307426601A5041959705 @default.
• W4307426601 hasAuthorship W4307426601A5046578778 @default.
• W4307426601 hasAuthorship W4307426601A5059685514 @default.
• W4307426601 hasAuthorship W4307426601A5065740152 @default.
• W4307426601 hasAuthorship W4307426601A5069841995 @default.
• W4307426601 hasAuthorship W4307426601A5075448540 @default.
• W4307426601 hasAuthorship W4307426601A5080751461 @default.
• W4307426601 hasAuthorship W4307426601A5084498269 @default.
• W4307426601 hasBestOaLocation W43074266011 @default.
• W4307426601 hasConcept C112930515 @default.
• W4307426601 hasConcept C118552586 @default.
• W4307426601 hasConcept C126322002 @default.
• W4307426601 hasConcept C138816342 @default.
• W4307426601 hasConcept C159110408 @default.
• W4307426601 hasConcept C170493617 @default.
• W4307426601 hasConcept C187212893 @default.
• W4307426601 hasConcept C199360897 @default.
• W4307426601 hasConcept C2775864247 @default.
• W4307426601 hasConcept C2778186239 @default.
• W4307426601 hasConcept C2779256446 @default.
• W4307426601 hasConcept C2779638493 @default.
• W4307426601 hasConcept C2780623815 @default.
• W4307426601 hasConcept C3019080777 @default.
• W4307426601 hasConcept C41008148 @default.
• W4307426601 hasConcept C524218345 @default.
• W4307426601 hasConcept C71924100 @default.
• W4307426601 hasConceptScore W4307426601C112930515 @default.
• W4307426601 hasConceptScore W4307426601C118552586 @default.
• W4307426601 hasConceptScore W4307426601C126322002 @default.
• W4307426601 hasConceptScore W4307426601C138816342 @default.
• W4307426601 hasConceptScore W4307426601C159110408 @default.
• W4307426601 hasConceptScore W4307426601C170493617 @default.
• W4307426601 hasConceptScore W4307426601C187212893 @default.
• W4307426601 hasConceptScore W4307426601C199360897 @default.
• W4307426601 hasConceptScore W4307426601C2775864247 @default.
• W4307426601 hasConceptScore W4307426601C2778186239 @default.
• W4307426601 hasConceptScore W4307426601C2779256446 @default.
• W4307426601 hasConceptScore W4307426601C2779638493 @default.
• W4307426601 hasConceptScore W4307426601C2780623815 @default.
• W4307426601 hasConceptScore W4307426601C3019080777 @default.
• W4307426601 hasConceptScore W4307426601C41008148 @default.
• W4307426601 hasConceptScore W4307426601C524218345 @default.
• W4307426601 hasConceptScore W4307426601C71924100 @default.
• W4307426601 hasFunder F4320334661 @default.
• W4307426601 hasIssue "1" @default.
• W4307426601 hasLocation W43074266011 @default.
• W4307426601 hasLocation W43074266012 @default.
• W4307426601 hasLocation W43074266013 @default.
• W4307426601 hasOpenAccess W4307426601 @default.
• W4307426601 hasPrimaryLocation W43074266011 @default.
• W4307426601 hasRelatedWork W1558050204 @default.
• W4307426601 hasRelatedWork W1974629898 @default.
• W4307426601 hasRelatedWork W2020460752 @default.

• next